(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 21.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Ginkgo Bioworks Holdings's revenue in 2024 is $251,455,000.On average, 3 Wall Street analysts forecast DNA's revenue for 2024 to be $474,773,310,080, with the lowest DNA revenue forecast at $468,146,083,455, and the highest DNA revenue forecast at $480,927,009,632. On average, 3 Wall Street analysts forecast DNA's revenue for 2025 to be $711,618,637,580, with the lowest DNA revenue forecast at $611,710,882,381, and the highest DNA revenue forecast at $857,299,241,564.
In 2026, DNA is forecast to generate $984,746,900,844 in revenue, with the lowest revenue forecast at $969,008,582,857 and the highest revenue forecast at $1,000,485,218,832.